Riverain signs on with Siemens March 24, 2023 -- Artificial intelligence software developer Riverain Technologies said that its ClearRead Bone Suppression software for chest x-rays is now available on Siemens Healthineers' Digital Marketplace.Read More
7-tesla MRI machine now operational in Germany March 24, 2023 -- A 7-tesla machine that's claimed to be one of Europe's most powerful MRI systems is now operational at Otto von Guericke University Magdeburg in Germany. The machine was formally inaugurated recently.Read More
Lunit secures CE Mark for 3D breast tomosynthesis March 24, 2023 -- Artificial intelligence (AI) software developer Lunit has secured the CE Mark under Europe's medical device regulation for its AI software for digital breast tomosynthesis, Lunit Insight DBT.Read More
Magnetic Insight highlights MPI scanner installation March 24, 2023 -- Magnetic Insight is highlighting the installation of a Momentum CT magnetic particle imaging (MPI) scanner at the Cyceron biomedical imaging research facility where the Blood and Brain and Caen Normandie Institute is hosted in Caen, France.Read More
Nuclidium wins award to study NET radiopharmaceutical March 21, 2023 -- Radiopharmaceutical developer Nuclidium and the University Hospital Basel, Switzerland, have received an Investigator Award from the Neuroendocrine Tumors Research Foundation to support a phase I trial of its TraceNET copper-based diagnostic radiopharmaceutical for neuroendocrine tumors (NETs).Read More
Brainomix secures FDA clearance for stroke AI software March 21, 2023 -- Artificial intelligence (AI) software developer Brainomix has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its flagship e-ASPECTS stroke imaging software.Read More
Uncovered: Draft MRI safety guidelines March 20, 2023 -- The American College of Radiology (ACR) has released a draft manual on MRI safety and is seeking feedback on the guidelines.Read More
Curium comments on supply challenges for Eclipse clinical trial March 20, 2023 -- Nuclear medicine company Curium confirmed in a recent statement that it doesn't expect supply challenges of its lutetium-177 prostate-specific membrane antigen with 3-iodo-D-tyrosine for the company's Eclipse phase III clinical trial.Read More